Evidence map›Paper›PMID 20117238›Full record

ArticleBiochimica et biophysica acta2010

HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Scott R Richmond, Michael J Carper, Xiaoyong Lei, Sheng Zhang, Kevin E Yarasheski, Sasanka Ramanadham

Abstract read
In one paragraph

Article in Biochimica et biophysica acta, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. miR-27a Regulates Sheep Adipocyte Differentiation by TargetingAnimals : an open access journal from MDPI · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Scott R RichmondDepartment of Internal Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
Michael J Carper
Xiaoyong Lei
Sheng Zhang
Kevin E Yarasheski
Sasanka Ramanadham
Washington University in St. Louis · US

Funding

Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2M
TRANSGENICS COREP60DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI SCHAFFER, JEAN E. · 1986 to 2012
$25.2M
Myocardial Function /FFA Metabolism in HIV Metabolic SynR01DK059531 · NIDDK · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2000 to 2008
$3.8M
CELL BIOLOGIC APPROACHES TO DIABETES RESEARCHT32DK007296 · NIDDK · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 1986 to 2014
$3.3M
CALCIUM-INDEPENDENT PLA2BETA IN BETA-CELL APOPTOSISR01DK069455 · NIDDK · WASHINGTON UNIVERSITY · PI RAMANADHAM, SASANKA · 2004 to 2013
$2.7M
PROTEIN TURNOVER AND ANABOLIC INTERVENTIONS IN AIDSR01DK049393 · NIDDK · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 1994 to 2008
$2.2M
Yoga for the Management of HIV-Metabolic SyndromesR21AT003083 · NCCIH · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2005 to 2007
$604k
EXERCISE AND PIOGLITAZONE FOR HIV CARDIOMETABOLIC SYNDROMESR56DK049393 · NIDDK · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2009 to 2009
$500k
Characterizing the HIV-Muscle Mitochondrial ProteomeR21DK074345 · NIDDK · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2005 to 2006
$415k
NCCIH NIH HHS R21 AT003083NIDDK NIH HHS DK049393NIDDK NIH HHS DK059531NIDDK NIH HHS DK074345NIDDK NIH HHS P30 DK056341NIDDK NIH HHS P30-DK-056341NIDDK NIH HHS P60 DK020579NIDDK NIH HHS P60-DK020579NIDDK NIH HHS R01 DK049393NIDDK NIH HHS R01 DK059531NIDDK NIH HHS R01 DK069455NIDDK NIH HHS R01-DK69455NIDDK NIH HHS R21 DK074345NIDDK NIH HHS R56 DK049393NIDDK NIH HHS T32 DK007296NIDDK NIH HHS T32-DK007296-27
6 · The paper itself

Abstract

Infection with human immunodeficiency virus (HIV) and treatment with HIV-protease inhibitor (PI)-based highly active antiretroviral therapies (HAART) is associated with dysregulated fatty acid and lipid metabolism. Enhanced lipolysis, increased circulating fatty acid levels, and hepatic and intramuscular lipid accumulation appear to contribute to insulin resistance in HIV-infected people treated with PI-based HAART. However, it is unclear whether currently prescribed HIV-PIs directly alter skeletal muscle fatty acid transport, oxidation, and storage. We find that ritonavir (r, 5micromol/l) plus 20micromol/l of atazanavir (ATV), lopinavir (LPV), or darunavir (DRV) reduce palmitate oxidation(16-21%) in differentiated C2C12 myotubes. Palmitate oxidation was increased following exposure to high fatty acid media but this effect was blunted when myotubes were pre-exposed to the HIV-PIs. However, LPV/r and DRV/r, but not ATV/r suppressed palmitate uptake into myotubes. We found no effect of the HIV-PIs on FATP1, FATP4, or FABPpm but both CD36/FAT and carnitine palmitoyltransferase 1 (CPT1) were reduced by all three regimens though ATV/r caused only a small decrease in CPT1, relative to LPV/r or DRV/r. In contrast, sterol regulatory element binding protein-1 was increased by all 3 HIV-PIs. These findings suggest that HIV-PIs suppress fatty acid oxidation in murine skeletal muscle cells and that this may be related to decreases in cytosolic- and mitochondrial-associated fatty acid transporters. HIV-PIs may also directly impair fatty acid handling and partitioning in skeletal muscle, and this may contribute to the cluster of metabolic complications that occur in people living with HIV.

Indexed as

AnimalsAtazanavir SulfateCarnitine O-PalmitoyltransferaseCD36 AntigensCell LineDarunavirDose-Response Relationship, DrugFatty AcidsFatty Acid Transport ProteinsHIV Protease InhibitorsHumansLopinavirMiceMuscle Fibers, SkeletalMuscle, SkeletalOligopeptidesAtazanavir SulfateCarnitine O-PalmitoyltransferaseCD36 AntigensDarunavirFatty AcidsFatty Acid Transport ProteinsHIV Protease InhibitorsLopinavirOligopeptidesPyridinesPyrimidinonesRitonavirSulfonamides

Identifiers

PMID20117238
PMCPMC2838954
OpenAlexW2036196325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.